SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
NCT00460798
·
clinicaltrials.gov ↗
COMPLETED
Status
356
Enrollment
INDUSTRY
Sponsor class
Conditions
Renal Cell Carcinoma
Interventions
OTHER:
Sutent: observational study
Sponsor
Pfizer